Global Induced Pluripotent Stem Cell (Ipsc) Market Size 2024, Forecast To 2033

The induced pluripotent stem cell (iPSC) market has experienced rapid growth, reaching $2.97 billion in 2023 and is expected to grow to $3.29 billion in 2024, reflecting a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period is attributed to increasing healthcare expenditure, a rise in funding, growing awareness of the medicinal potential of stem cell products, the use of iPSC-based drug discovery, increasing demand for personalized medicine, and the cost-effective benefits of iPSC for drug discovery. Moving towards 2028, the market is expected to continue its rapid growth, targeting a size of $4.81 billion at a CAGR of 10.0%. The anticipated growth is fueled by factors such as an increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, rising prevalence of genetic diseases, government initiatives, and a rapid increase in technology. Key trends in the forecast period include the development of pluripotent stem cells for Parkinson’s disease (PD), strategic collaborations and partnerships, the development of iPSC-derived NK cells, iPSC for cell therapy, investment in regenerative medicine research and development, development of iPSC expansion medium, development of personalized iPSC, and the development of pluripotent stem cells for type I diabetes.